Nuvilex, Inc. (OTCQB: NVLX), an emerging biotechnology provider of cell and gene therapy solutions, today provided additional details based on the Goldman Small Cap Research report issued February 29, 2012, that highlighted the company’s cell encapsulation technology and its benefits for treating chronic diseases such as diabetes. The Company’s technology involves encapsulating insulin-producing cells that respond to changes in glucose levels into the Cell-in-a-Box® platform. As a result, the treatment would potentially eliminate the need for diabetes patients to continually test their glucose levels and inject insulin.
The Goldman report cited the completed animal study wherein SG Austria successfully treated diabetes in an established, recognized animal model utilizing live encapsulated cells. In the study, the introduced cells responded to elevated blood sugar levels by producing insulin, thereby alleviating the symptoms of diabetes. Moreover, encapsulated cells remained viable and responsive for many months.
The report stated, “This data, as well as previously published results, demonstrate it is feasible to overcome the basis for diabetes by implanting encapsulated, insulin-producing cells. This should pave the way for future clinical trials of encapsulated cells as a means to continuously regulate blood glucose for months, eliminating the need for daily glucose assessment and insulin injections. Such treatment would present a more natural means of providing insulin to patients, mimicking the body's own insulin production and thereby maintaining healthy blood glucose levels.
“The long term effects of diabetes include kidney failure, blindness, heart disease, amputations, and stroke. The World Health Organization (WHO) reports 346 million people in the world have diabetes and 4 million deaths occur globally each year. In fact, more than $378 billion is spent annually on diabetes treatment with the number expected to rise to $490 billion by 2030.”The report concluded that, “Although it is early in the development process, the prospects on the diabetes front could be huge for the Company.” Goldman set a current value of Nuvilex at $0.30 per share with a six month price target of $0.50 per share based on the cell encapsulation technology and the favorable clinical and pre-clinical trial results across multiple biotechnology fields.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV